You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Abivax reports promising rheumatoid arthritis results

Clinical-stage biotechnology company, Abivax, has reported promising results from its phase 2a maintenance trial into rheumatoid arthritis (RA) after one year of continued daily treatment with 50mg ABX464.